In summary, the add-on of GLP1-RA and/or SGLT2i to insulin therapy can reduce the dose of insulin, or even allow for its withdrawal (in the case of preserved insulin reserve, primarily in patients diagnosed with diabetes in recent years), as well as achieve an ideal triad in the treatment (good glycaemic control with no weight gain and reduced risk of hypoglycaemia), with the added advantage of cardiorenal benefits. Here, GCG is linked to diabetes mellitus.